News | May 18, 2021
Shilpa Medicare to produce 50 mn doses of Sputnik V Vaccine
Targeted production of the dual vector Sputnik V for the first 12 months is 50 million doses from the date of start of commercial production
Targeted production of the dual vector Sputnik V for the first 12 months is 50 million doses from the date of start of commercial production
The outlook for the US business remains good as respiratory pipeline (gAbraxane, gAdvair, gDulera) adds medium-term growth visibility.
Dr. Reddy's has the rights to distribute 250mn doses in India
India sales grew 23.5% YoY with consolidation of Wockhardt products
The company plans to aggressively invest in longer gestation period projects like innovation, biosimilars, vaccines, etc.
Financial support is being provided as a grant from the Government of India
The company is working closely with its six manufacturing partners in India
The company will provide one crore tablets every week, starting from 12th May 2021, aggregating to 16 crore tablets worth Rs. 8 crores over the next 4 months
Proactively engaging with foreign vaccine manufacturers like Moderna, Pfizer etc., to apply for Emergency Use Authorization in India so that these vaccines can be easily imported and made available in India
The deal is to sell one of the two business undertakings of ZAHL for a lump sum consideration of Rs. 2921 crores on a cash free and debt free basis,
Subscribe To Our Newsletter & Stay Updated
